Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
JAMASep 8, 2026
Ting Zhou, Huaqiang Zhou, Fangfang Gao et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring concurrent EGFR and TP53 mutations. The study found that the median progression-free survival was significantly longer with the combination therapy at 34.0 months compared to 15.6 months for monotherapy.
Key findings
- Median progression-free survival was 34.0 months for osimertinib plus chemotherapy versus 15.6 months for osimertinib alone.
- The hazard ratio for progression-free survival was 0.44, indicating a significant benefit for combination therapy.
- The incidence of grade 3 or higher treatment-related adverse events was higher in the combination group.
Why it matters
The findings suggest that combining osimertinib with chemotherapy may enhance treatment outcomes for patients with specific genetic mutations in advanced NSCLC, potentially guiding personalized treatment strategies.